OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study.
暂无分享,去创建一个
R. Maciuca | J. Mansfield | D. Rubin | L. Peyrin-Biroulet | B. Feagan | U. Arulmani | H. Tyrrell | J. Thommes | S. Tole